Johannes PM Langedijk

Dr. Johannes PM Langedijk


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
AKAnders Krarup
Anders Krarup
DTDaphné Truan
Daphné Truan
PFPolina Furmanova-Hollenstein
Polina Furmanova-Hollenstein
LBLies Bogaert
Lies Bogaert
PBPascale Bouchier
Pascale Bouchier
JLJohannes PM Langedijk
Johannes PM Langedijk
Respiratory syncytial virus (RSV) causes acute lower respiratory tract infections and is the leading cause of infant hospitalizations. Recently, a promising vaccine antigen based on the RSV fusion protein (RSV F) stabilized in the native prefusion conformation has been described. Here we report alternative strategies to arrest RSV F in the prefusion conformation based on the prevention of hinge movements in the first refolding region and the elimination of proteolytic exposure of the fusion peptide. A limited number of unique mutations are identified that stabilize the prefusion conformation of RSV F and dramatically increase expression levels. This highly stable prefusion RSV F elicits neutralizing antibodies in cotton rats and induces complete protection against viral challenge. Moreover, the structural and biochemical analysis of the prefusion variants suggests a function for p27, the excised segment that precedes the fusion peptide in the polypeptide chain.

28 September 2020 in npj Vaccines
Verified
Journal Article
Open access
PDF file
RBRinke Bos
Rinke Bos
LRLucy Rutten
Lucy Rutten
JLJoan E. M. van der Lubbe
Joan E. M. van der Lubbe
MBMark J. G. Bakkers
Mark J. G. Bakkers
GHGijs Hardenberg
Gijs Hardenberg
HSHanneke Schuitemaker
Hanneke Schuitemaker
Development of effective preventative interventions against SARS-CoV-2, the etiologic agent of COVID-19 is urgently needed. The viral surface spike (S) protein of SARS-CoV-2 is a key target for prophylactic measures as it is critical for the viral replication cycle and the primary target of neutralizing antibodies. We evaluated design elements previously shown for other coronavirus S protein-based vaccines to be successful, e.g., prefusion-stabilizing substitutions and heterologous signal peptides, for selection of a S-based SARS-CoV-2 vaccine candidate. In vitro characterization demonstrated that the introduction of stabilizing substitutions (i.e., furin cleavage site mutations and two consecutive prolines in the hinge region of S2) increased the ratio of neutralizing versus non-neutralizing antibody binding, suggestive for a prefusion conformation of the S protein. Furthermore, the wild-type signal peptide was best suited for the correct cleavage needed for a natively folded protein. These observations translated into superior immunogenicity in mice where the Ad26 vector encoding for a membrane-bound stabilized S protein with a wild-type signal peptide elicited potent neutralizing humoral immunity and cellular immunity that was polarized towards Th1 IFN-γ. This optimized Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in a phase I clinical trial (ClinicalTrials.gov Identifier: NCT04436276).

11 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JJJarek Juraszek
Jarek Juraszek
LRLucy Rutten
Lucy Rutten
SBSven Blokland
Sven Blokland
PBPascale Bouchier
Pascale Bouchier
RVRichard Voorzaat
Richard Voorzaat
JLJohannes PM Langedijk
Johannes PM Langedijk
The trimeric spike (S) protein of SARS-CoV-2 is the primary focus of most vaccine design and development efforts. Due to intrinsic instability typical of class I fusion proteins, S tends to prematurely refold to the post-fusion conformation, compromising immunogenic properties and prefusion trimer yields. To support ongoing vaccine development efforts, we report the structure-based design of soluble S trimers with increased yields and stabilities, based on introduction of single point mutations and disulfide-bridges. We identify regions critical for stability: the heptad repeat region 1, the SD1 domain and position 614 in SD2. We combine a minimal selection of mostly interprotomeric mutations to create a stable S-closed variant with a 6.4-fold higher expression than the parental construct while no longer containing a heterologous trimerization domain. The cryo-EM structure reveals a correctly folded, predominantly closed pre-fusion conformation. Highly stable and well producing S protein and the increased understanding of S protein structure will support vaccine development and serological diagnostics.

1 April 2018 in Cell Reports
Verified
Journal Article
Open access
LRLucy Rutten
Lucy Rutten
YLYen-Ting Lai
Yen-Ting Lai
SBSven Blokland
Sven Blokland
DTDaphne Truan
Daphne Truan
IBIlona J.M. Bisschop
Ilona J.M. Bisschop
JLJohannes PM Langedijk
Johannes PM Langedijk
The heavily glycosylated native-like envelope (Env) trimer of HIV-1 is expected to have low immunogenicity, whereas misfolded forms are often highly immunogenic. High-quality correctly folded Envs may therefore be critical for developing a vaccine that induces broadly neutralizing antibodies. Moreover, the high variability of Env may require immunizations with multiple Envs. Here, we report a universal strategy that provides for correctly folded Env trimers of high quality and yield through a repair-and-stabilize approach. In the repair stage, we utilized a consensus strategy that substituted rare strain-specific residues with more prevalent ones. The stabilization stage involved structure-based design and experimental assessment confirmed by crystallographic feedback. Regions important for the refolding of Env were targeted for stabilization. Notably, the α9-helix and an intersubunit β sheet proved to be critical for trimer stability. Our approach provides a means to produce prefusion-closed Env trimers from diverse HIV-1 strains, a substantial advance for vaccine development.

8 May 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MGMorgan S. A. Gilman
Morgan S. A. Gilman
PFPolina Furmanova-Hollenstein
Polina Furmanova-Hollenstein
GPGabriel Pascual
Gabriel Pascual
AWAngélique B. van ‘T Wout
Angélique B. van ‘T Wout
JLJohannes PM Langedijk
Johannes PM Langedijk
JMJason McLellan
Jason McLellan
The respiratory syncytial virus (RSV) F glycoprotein is a class I fusion protein that mediates viral entry and is a major target of neutralizing antibodies. Structures of prefusion forms of RSV F, as well as other class I fusion proteins, have revealed compact trimeric arrangements, yet whether these trimeric forms can transiently open remains unknown. Here, we perform structural and biochemical studies on a recently isolated antibody, CR9501, and demonstrate that it enhances the opening of prefusion-stabilized RSV F trimers. The 3.3 Å crystal structure of monomeric RSV F bound to CR9501, combined with analysis of over 25 previously determined RSV F structures, reveals a breathing motion of the prefusion conformation. We also demonstrate that full-length RSV F trimers transiently open and dissociate on the cell surface. Collectively, these findings have implications for the function of class I fusion proteins, as well as antibody prophylaxis and vaccine development for RSV.

1 March 2020 in Cell Reports
Verified
Journal Article
Open access
LRLucy Rutten
Lucy Rutten
MGMorgan S.A. Gilman
Morgan S.A. Gilman
SBSven Blokland
Sven Blokland
JJJarek Juraszek
Jarek Juraszek
JMJason McLellan
Jason McLellan
JLJohannes PM Langedijk
Johannes PM Langedijk
Ebola virus causes severe hemorrhagic fever, often leading to death in humans. The trimeric fusion glycoprotein (GP) is the sole target for neutralizing antibodies and is the major focus of vaccine development. Soluble GP ectodomains are unstable and mostly monomeric when not fused to a heterologous trimerization domain. Here, we report structure-based designs of Ebola and Marburg GP trimers based on a stabilizing mutation in the hinge loop in refolding region 1 and substitution of a partially buried charge at the interface of the GP1 and GP2 subunits. The combined substitutions (T577P and K588F) substantially increased trimer expression for Ebola GP proteins. We determined the crystal structure of stabilized GP from the Makona Zaire ebolavirus strain without a trimerization domain or complexed ligand. The structure reveals that the stabilized GP adopts the same trimeric prefusion conformation, provides insight into triggering of GP conformational changes, and should inform future filovirus vaccine development.